New research suggests that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who end traditional lifestyle programs.
Published data in a major medical journal shows that while obese people often shed about a fifth of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"People using these treatments should be aware of the risk of quick weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to starting weight within about one and a half years.
Weighing Approaches
The research, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of these new drugs with older methods.
Researchers note that people who lose weight through dieting usually see a slower weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts propose the mode of action of the jabs explains the accelerated weight return.
These medications copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations several times higher than normal might result in the body to produce less of its own natural hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making overeating far more likely."
A Lifelong Condition?
Health authorities advise the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, given the high risk of relapse, the treatment is often long-term.
This view is echoed by pharmaceutical companies, who say that the results "underscore the chronic nature of obesity," akin to managing conditions like hypertension.
User Testimonies
Users who have come off the jabs report a intense return of hunger.
"I experienced a trigger flipping and you're instantly ravenous," recalled one woman.
This challenge is worsened if users have not established sustainable dietary or behavioural changes during therapy.
Growing Adoption
Recent estimates suggest that millions of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is greater among females compared to males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, experts stress that while these medications are effective tools for shedding pounds, they are not a standalone cure and long-term success relies on integrated behavioural management.
